ABSTRACT:
The potential of CAR-T cells, espicially after the devellopment of 3rd Generation CAR-T, have made immunotherapy one of the most promising therapeutic intervention. However, the ex-vivo manufacturing of CAR-T cells combined with physiological complications majorly because of Cytokine Release Syndrome, still makess the therapy having an uncertainty. Furthermore, the it takes around 4-5 weeks to engineer CAR-T cells ex-vivo which makes in-vivo manufacturing of CAR-T cells a repalcing mechanism to develop CAR-T cells. The specificty of CAR-T cells is another concern, which is can be witnessed in the form of antigen-escape mechanisms, which ,makes the modality having uncertain prognostic outcomes. Nevertheless, CAR-T cells have proved to be a potential interventional immunotherapy, because of design, which stimulates the release of cytokines as soon as it ineracts with any surface-antigen and having no dependence on MHC-complex, makes CAR-T cell an intervention which needs to be augmented.
Therefore, in-vivo manufacturing of CAR-T cells using a viral-vector platform (lentil-viral vector or AAV-vector used for transfection) or incorporation of nanoparticles/Biomaterials is a better alternative. This will decrese the cost of manufacturing CAR-T cells and will save time us time, which will make the theraputic delivery flexible (CAR-T cells can be manufactured in accordance to the identified Biomarkers). To enhance the specificity of CAR-T cells, AI tools combined with the various gentic datasets can make CAR-T cell therapy a common interventional platform not only for malignancies but also for disorders like Cystic Fibrosis. Platforms like onco AI (designed by a specific algorithm) will aid in an early prediction of potential Biomarkers making personalized CAR-T cell immunotherapy a reality. To uncertainities of any cytotoxicities (CRS) and nuerotoxicities to eradicate any chances of poor prognostic outcomes TensorFlow AI (designed by a specific Algorithm) can help us in computational-simulation of the therapy, even before manufacturing the CAR-T cell, ensuring credibility and efficacy of CAR-T cell before any adversities.
These two AI tools gievs a future CAR-AIT cell immunotherapy which will be nothing but an algorithm programmed specifically to develop an AI-Theeapeutic Interventional modality driven by the idea of a common CAR-T cell.
- Badges
- Science topic